Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SERA

SERA - Sera Prognostics, Inc. Stock Price, Fair Value and News

$2.11+0.12 (+6.03%)
Market Closed

29/100

SERA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

29/100

SERA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SERA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SERA Price Action

Last 7 days

8.2%

Last 30 days

-18.5%

Last 90 days

-39.9%

Trailing 12 Months

-47.6%

SERA RSI Chart

SERA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SERA Valuation

Market Cap

104.5M

Price/Earnings (Trailing)

-3.2

Price/Sales (Trailing)

1.1K

Price/Free Cashflow

-3.99

SERA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

SERA Fundamentals

SERA Revenue

Revenue (TTM)

95.0K

Rev. Growth (Yr)

-44.83%

Rev. Growth (Qtr)

-5.88%

SERA Earnings

Earnings (TTM)

-32.6M

Earnings Growth (Yr)

1.33%

Earnings Growth (Qtr)

2.88%

SERA Profitability

Return on Equity

-39.7%

Return on Assets

-30.17%

Free Cashflow Yield

-25.04%

SERA Investor Care

Shares Dilution (1Y)

50.56%

Diluted EPS (TTM)

-0.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025115.0K108.0K95.0K0
20240230.0K136.0K118.0K
2023330.0K375.0K330.0K306.0K
2022107.0K165.0K229.0K268.0K
202139.3K53.5K67.8K82.0K
202000025.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Sera Prognostics, Inc.

SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
 CEO
 WEBSITEhttps://seraprognostics.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES87

Sera Prognostics, Inc. Frequently Asked Questions

SERA is the stock ticker symbol of Sera Prognostics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Sera Prognostics, Inc. is 104.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, SERA's PE ratio (Price to Earnings) is -3.2 and Price to Sales (PS) ratio is 1.1 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SERA PE ratio will change depending on the future growth rate expectations of investors.